Galapagos Sells CRO To Selvita For €31.2m
Fidelta No Longer Fits Strategy
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
